Format

Send to

Choose Destination
Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0734-7. [Epub ahead of print]

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.

Author information

1
Clinical Hematology Department, Institut Català d'Oncologia, Barcelona, Spain.
2
EBMT Paris Study Office, Paris, France.
3
Pathology Department, Hospital Universitari Bellvitge, Barcelona, Spain.
4
BMT Unit Dept. of Hematology L, 4042, Rigshospitalet, Copenhagen, Denmark.
5
Hematology Department, Karolinksa University Hospital, Stockholm, Sweden.
6
Haematologie/Onkologie/Stammzelltransplantation, Evangelisches Krankenhaus Essen-Werden, Essen, Germany.
7
Hematopoietic SCT Unit, Florence Nightingale Sisli Hospital, Istambul, Turkey.
8
Department of Hematology, Radboud University-Nijmegen Medical Centre, Nijmegen, The Netherlands.
9
Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
10
Hematology and BMT Department, Beilinson Hospital, Petach_Tikva, Israel.
11
Hematology, Hospital C. Panico, Tricase_Lecce, Italy.
12
Sheffield Teaching Hospitals NHS Trust, Sheffield, UK.
13
Dept. of Medicine -Hematology, Oncology, University of Freiburg, Freiburg, Germany.
14
Department of Haemato-oncology, St. Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
15
Clinical Hematology Department, Institut Català d'Oncologia, Barcelona, Spain. asureda@iconcologia.net.
16
Medizinische Klinik V, University of Heidelberg, Heidelberg, Germany.

Abstract

Systemic anaplastic large cell lymphoma (sALCL) is a rare histological entity expressing the CD30 antigen that comprises around 11% of peripheral T-cell lymphoma. We analysed the outcome of patients with relapsed/refractory sALCL treated with autologous stem cell transplantation (auto-HCT). We included 65 adult patients (42 males; median age, 44 years); 24 patients had an ALK-ve sALCL. Fifty-one patients had chemosensitive disease at the time of transplant. Ten patients (15%) were treated with brentuximab vedotin (BV) before auto-HCT (median number of doses: 5). The median follow-up for surviving patients was 35 months (3-71). Three-year cumulative incidence of nonrelapse mortality and of relapse were 1.7% and 34%, respectively. Three-year progression-free survival and overall survival were 64% and 73%, respectively. No prognostic factors for any of the outcomes analysed were found in univariate analysis. There were no significant differences in any of the outcomes between patients who had received BV and the remainder. This is the largest analysis presented so far analysing the role of auto-HCT in patients with relapsed/refractory sALCL, showing a promising PFS and OS in this high-risk population. The potential impact of the administration of BV as salvage strategy before the procedure needs to be further elucidated.

PMID:
31695174
DOI:
10.1038/s41409-019-0734-7

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center